Medicament for Preventing and/or Treating Ischemic Cardiovascular Disease

1 - 19 . (canceled)

20 . A method for preventing and/or treating an ischemic cardiovascular disease characterized by administering a medicament comprising as an active ingredient a compound of an aminobenzenesulfonic acid derivative represented by the following general formula (I):

(wherein R 1 represents a hydrogen atom, a C 1 -C 6 alkyl group, a C3-C 7 cycloalkyl group, a halogenated C 1 -C 4 alkyl group, a halogen atom or a C 6 -C 12 aryl group; R 2 represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 7 -C 12 aralkyl group which may have one or more substituents selected from the group consisting of a cyano group, a nitro group, a C 1 -C 6 alkoxy group, a halogen atom, a C 1 -C 6 alkyl group and an amino group; and n represents an integer of 1 to 4) or a salt thereof, or a hydrate or solvate thereof to a patient undergoing percutaneous coronary intervention.

21 . The method according to claim 20 , wherein the ischemic cardiovascular disease is myocardial infarction or angina pectoris.

22 . The method according to claim 21 , wherein the myocardial infarction is ST-segment elevation myocardial infarction.

23 . The method according to claim 22 , wherein the ST-segment elevation myocardial infarction is anterior ST-segment elevation myocardial infarction.

24 . The method according to claim 20 , wherein the substitution position of R 1 is the 5-position.

25 . The method according to claim 20 , wherein n is 2.

26 . The method according to claim 20 , wherein R 2 is a hydrogen atom, a C 1 -C 3 alkyl group or a C 7 -C 12 aralkyl group which may have one or more substituents selected from a C 1 -C 3 alkyl group, a C 1 -C 3 alkoxy group and a halogen atom.

27 . The method according to claim 20 , wherein R 2 is a C 7 -C 12 aralkyl group which may have one or more substituents selected from a hydrogen atom and a C 1 -C 3 alkoxy group.

28 . The method according to claim 20 , wherein R 2 is a hydrogen atom.

29 . The method according to claim 20 , wherein R 1 is a hydrogen atom, a C 1 -C 6 alkyl group, a C 5 -C 6 cycloalkyl group, a trifluoromethyl group, a halogen atom or a phenyl group.

30 . The method according to claim 20 , wherein R 1 is a C 1 -C 3 alkyl group, a cyclohexyl group, a trifluoromethyl group, a chlorine atom, a bromine atom or a phenyl group.

31 . The method according to claim 20 , wherein R 1 is a methyl group or a propyl group.

32 . The method according to claim 20 , wherein the active ingredient is selected from the following compounds:

5-methyl-2-(1-piperazinyl)benzenesulfonic acid; 5-trifluoromethyl-2-(1-piperazinyl)benzenesulfonic acid;

5-n-propyl-2-(1-piperazinyl)benzenesulfonic acid; 5-phenyl-2-(1-piperazinyl)benzenesulfonic acid; 5-chloro-2-(1-piperazinyl)benzenesulfonic acid; 5-bromo-2-(1-piperazinyl)benzenesulfonic acid; 5-iso-propyl-2-(1-piperazinyl)benzenesulfonic acid; 5-cyclohexyl-2-(1-piperazinyl)benzenesulfonic acid; 5-n-propyl-2-(1-homopiperazinyl)benzenesulfonic acid;

5-n-propyl-2-[4-(2,3,4-trimethoxybenzyl)-1-piperazinyl)benzenesulfonic acid; and

5-n-propyl-2-[4-(3,4-dimethoxybenzyl)-1-piperazinyl)benzenesulfonic acid.

33 . The method according to claim 32 , wherein the active ingredient is selected from the following compounds:

5-methyl-2-(1-piperazinyl)benzenesulfonic acid; and

5-n-propyl-2-(1-piperazinyl)benzenesulfonic acid.

34 . The method according to claim 20 , wherein the active ingredient is 5-methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate.

35 . A method for preventing and/or treating anterior ST-segment elevation myocardial infarction, comprising administering a medicament comprising as an active ingredient 5-methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate to a patient undergoing percutaneous coronary intervention.

36 . The method according to claim 20 , wherein the patient undergoing percutaneous coronary intervention has TIMI flow grade 0 or 1.

37 . The method according to claim 20 , wherein administration of the active ingredient is initiated before percutaneous coronary intervention is performed.

38 . The method according to claim 20 , wherein the active ingredient is continuously administered intravenously for 48 hours.